Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Vernal keratoconjunctivitis (VKC) is an allergic eye disease. It is a multifactorial Th2 cell-mediated ocular surface inflammatory state that primarily affects males, specifically to children. Intense itching, burning, photophobia, and tears are the most common symptoms. The most common signs are conjunctival hyperaemia, superficial keratitis, and giant papillae. The overexpression of mast cells, Th2 cells, cytokines, eosinophils, adhesion molecules, chemokines, and cytokines are characteristics of the vernal keratoconjunctivitis. Limbal infiltration, corneal involvement, conjunctival fibroproliferative lesions, and conjunctival hyperemia are the features of vernal keratoconjunctivitis. Mixed, palpebral, and limbal are the three types of vernal keratoconjunctivitis, which are based on the main anatomical site of the papillary reaction.

The global vernal keratoconjunctivitis market is estimated to be valued at US$ 346.9 million in 2021 and is expected to exhibit a CAGR of 3.6% during the forecast period (2021-2028).

Figure 1.Global Vernal Keratoconjunctivitis Market Value (US$ million), By Region, 2021

Vernal Keratoconjunctivitis  | Coherent Market Insights

Key players operating in the global vernal keratoconjuctivities market are focusing on drug approvals, which is anticipated to drive the market growth during the forecast period.

Increasing drug approvals provides the opportunity to provide patients with novel treatment  options, which is projected to boost the market growth during the forecast period. For instance, in June 2021, Santen Pharmaceutical Co., Ltd. announced that U.S. Food and Drug Administration (FDA) approved a new drug verkazia (Cyclosporine Ophthalmic Emulsion, 0.1%) for the treatment of vernal keratoconjunctivitis (VKC) in children as well as adults.

Figure 2.Global Vernal Keratoconjuctivities Market Share (%) in Terms of Value, By Dosage Form, 2021

Vernal Keratoconjunctivitis  | Coherent Market Insights

Growing incidences of vernal keratoconjuctivities in young adults and children living in warm environment, is estimated to spur the market growth during the forecast period.

Rising incidences of vernal keratoconjuctivities mainly in young adults and children living in warm environment, is anticipated to boost the market growth during the forecast period. In dark-skinned population from Africa and India, the limbal form of vernal keratoconjunctivities is seen most frequently. For instance, in August 2021, Western Europe incidences were 3.2 in 10,000, whereas in Italy, a country with a Mediterranean climate, a higher prevalence ranging from 2.4 to 27.8 in 10,000 were observed.

request-sample

Vernal Keratoconjuctivities Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 346.9 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 3.6% 2028 Value Projection: US$ 443.0 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Bertilimumab, Verkazia, Lodoxamide, Tacrolimus, Antolimab, Nomacopan, Others
  • By Treatment: Mast Cell Stabilizers, Antihistamines, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Topical Corticosteroids, Cyclosporine, Tacrolimus, Others
  • By Dosage Form: Gel, Ointment, Tablet, Others
  • By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Companies covered:

Santen, Novartis Pharmaceuticals, Senju Pharmaceutical, Allakos, iCo Therapeutics, and Akari Therapeutics

Growth Drivers:
  • Rising prevalence of vernal keratoconjunctivities in male
  • Increasing incidences in young adults and children living in warm climate
Restraints & Challenges:
  • No precise diagnostic criteria for vernal keratoconjunctivitis

Global Vernal Keratoconjunctivitis Market– Impact of Coronavirus (COVID-19) Pandemic

Several clinicians and patients requested better suggestion for the treatment of vernal keratoconjunctivities patients in the COVID-19 pandemic. Most of the patients and doctors were following the recommendations given by scientific societies such as Indian Journal of Ophthalmology. Recently, considering the various difficulties associated with the COVID-19 pandemic, despite the fact that patients require treatments, vernal keratoconjuctivitis has not been prioritised. Topical medicines are the primary line of treatment for types of vernal keratoconjuctivitis with topical corticosteroids added in severe cases of vernal keratoconjunctivitis, even in the patients are at risk of COVID-19.

Global Vernal Keratoconjunctivitis Market: Restraint

There is no precise diagnostic criteria for vernal keratoconjunctivitis, which is anticipated to hamper the market growth during the forecast period. The vernal keratoconjunctivitis disease's distinctive signs and symptoms are used to detect the diagnosis. Several mild or unusual instances may be undetected as no exact diagnostic criteria is been developed.

Key Players

Major players operating in the global vernal keratoconjunctivitis market include Santen, Novartis Pharmaceuticals, Senju Pharmaceutical, Allakos, iCo Therapeutics, and Akari Therapeutics

The inner surface of the eyelid is lined with conjunctiva, a translucent tissue layer. When infected, this tissue tends to cover the white area of the eye and turn red or pink. As a result, the eye ailment conjunctivitis is often known as pink eye. The infection of the eye known as conjunctivitis is a common symptom of this ophthalmic condition. Infectious causes includes bacterial and viral infections, while non-infectious causes include allergy and immune-mediated illness inflammation. It is categorised into acute conjunctivitis, super acute conjunctivitis, and chronic conjunctivitis.

Vernal keratoconjunctivitis (VKC) is a chronic, multifactorial Th2-cell-mediated inflammatory disease of the ocular surface. It is distinguished by a large papilla on the upper tarsal conjunctiva and a corneoscleral junction. Hyperemia and mucus discharge are typical symptoms of VKC. There is no set standard treatment strategy for VKC. Mast cell stabilisers, antihistamines, nonsteroidal anti-inflammatory medications (NSAIDs), topical corticosteroids, and cyclosporine are available as treatments. Individuals receiving treatment should be continuously observed for the development of any ocular problems.

Market Dynamics

Increasing R&D activities in vernal keratoconjunctivitis for a better understanding of the disease is expected to drive the growth of global vernal keratoconjunctivitis market during the forecast period. In addition, increasing prevalence of vernal keratoconjuctivitis and supportive therapies have built the interest in several pharmaceutical companies in developing a cure for the disease. A greater knowledge of the disease's biology and manifestation of the disease has boosted efforts to develop improved treatment alternatives in the form of pipeline treatments, which is projected to propel the global vernal keratoconjunctivitis market share during the forecast period.

Key features of the study:

  • This report provides an in-depth analysis of the global vernal keratoconjunctivitis market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global vernal keratoconjunctivitis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
  • Key companies covered as a part of this study include Santen, Novartis Pharmaceuticals, Senju Pharmaceutical, Allakos, iCo Therapeutics, and Akari Therapeutics.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global vernal keratoconjunctivitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global vernal keratoconjunctivitis market

Detailed Segmentation:

  • Global Vernal Keratoconjunctivitis Market, By Drug Type :
    • Bertilimumab
    • Verkazia
    • Lodoxamide
    • Tacrolimus
    • Antolimab 
    • Nomacopan
    • Others
  • Global Vernal Keratoconjunctivitis Market, By Treatment:
    • Mast Cell Stabilizers
    • Antihistamines
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • Topical Corticosteroids
    • Cyclosporine
    • Tacrolimus
    • Others
  • Global Vernal Keratoconjunctivitis Market, By Dosage Form:
    • Gel
    • Ointment
    • Tablet
    • Others
  • Global Vernal Keratoconjunctivitis Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Vernal Keratoconjunctivitis Market, By Region:
    • North America
      • By Drug Type
        • Bertilimumab
        • Verkazia
        • Lodoxamide
        • Tacrolimus
        • Antolimab 
        • Nomacopan
        • Others
      • By Treatment
        • Mast Cell Stabilizers
        • Antihistamines
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Topical Corticosteroids
        • Cyclosporine
        • Tacrolimus
        • Others
      • By Dosage Form
        • Gel
        • Ointment
        • Tablet
        • Others
      • By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By  Drug Type
        • Bertilimumab
        • Verkazia
        • Lodoxamide
        • Tacrolimus
        • Antolimab 
        • Nomacopan
        • Others
      • By Treatment
        • Mast Cell Stabilizers
        • Antihistamines
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Topical Corticosteroids
        • Cyclosporine
        • Tacrolimus
        • Others
      • By Dosage Form
        • Gel
        • Ointment
        • Tablet
        • Others
      • By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type
        • Bertilimumab
        • Verkazia
        • Lodoxamide
        • Tacrolimus
        • Antolimab 
        • Nomacopan
        • Others
      • By Treatment
        • Mast Cell Stabilizers
        • Antihistamines
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Topical Corticosteroids
        • Cyclosporine
        • Tacrolimus
        • Others
      • By Dosage Form
        • Gel
        • Ointment
        • Tablet
        • Others
      • By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type
        • Bertilimumab
        • Verkazia
        • Lodoxamide
        • Tacrolimus
        • Antolimab 
        • Nomacopan
        • Others
      • By Treatment
        • Mast Cell Stabilizers
        • Antihistamines
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Topical Corticosteroids
        • Cyclosporine
        • Tacrolimus
        • Others
      • By Dosage Form
        • Gel
        • Ointment
        • Tablet
        • Others
      • By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type
        • Bertilimumab
        • Verkazia
        • Lodoxamide
        • Tacrolimus
        • Antolimab 
        • Nomacopan
        • Others
      • By Treatment
        • Mast Cell Stabilizers
        • Antihistamines
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Topical Corticosteroids
        • Cyclosporine
        • Tacrolimus
        • Others
      • By Dosage Form
        • Gel
        • Ointment
        • Tablet
        • Others
      • By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By  Drug Type
        • Bertilimumab
        • Verkazia
        • Lodoxamide
        • Tacrolimus
        • Antolimab 
        • Nomacopan
        • Others
      • By Treatment
        • Mast Cell Stabilizers
        • Antihistamines
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Topical Corticosteroids
        • Cyclosporine
        • Tacrolimus
        • Others
      • By Dosage Form
        • Gel
        • Ointment
        • Tablet
        • Others
      • By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Santen *
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Novartis Pharmaceuticals
    • Senju Pharmaceutical
    • Allakos
    • iCo Therapeutics
    • Akari Therapeutics

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Type
      • Market Snapshot, By Treatment
      • Market Snapshot, By Dosage Form
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunity
    • Impact Analysis
    • Pipeline Analysis
    • Regulatory Scenario
    • Market Trends
    • Key Developments
    • Epidemiology
    • PEST Analysis
    • Brand Analysis
  4. Global Vernal Keratoconjunctivitis Market– Impact of Coronavirus (COVID-19) Pandemic
    • COVID-19 Epidemiology
    • Supply and Demand Analysis
    • Key Developments
  5. Global Vernal Keratoconjunctivitis Market, By Drug Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
    • Bertilimumab
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Verkazia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Lodoxamide
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Tacrolimus
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Antolimab 
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Nomacopan
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  6. Global  Vernal Keratoconjunctivitis Market, By Treatment, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
    • Mast Cell Stabilizers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Antihistamines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Topical Corticosteroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Cyclosporine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Tacrolimus
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  7. Global Vernal Keratoconjunctivitis Market, By Dosage Form, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
    • Gel
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Ointment
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Tablet
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  8. Global Vernal Keratoconjunctivitis Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
    • Hospital Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Retail Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Online Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
  9. Global Vernal Keratoconjunctivitis Market, By Region, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2028
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type , 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • U.K.
        • Germany
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries/Region, 2017 – 2028, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  10. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Santen
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Novartis Pharmaceuticals
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Senju Pharmaceutical
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Allakos
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • iCo Therapeutics
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Akari Therapeutics
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
    • Analyst Views
  11. Section
    • Research Methodology
    • About us

*Browse 30 market data tables and 36 figures on "Global Vernal Keratoconjunctivitis Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The global vernal keratoconjunctivitis market is estimated to be valued at US$ 346.9 million in 2021 and is expected to exhibit a CAGR of 3.6 % between 2021 and 2028.
Increasing prevalence of vernal keratoconjunctivities in male is the factor which is expected to drive the market growth during the forecast period.
Tacrolimus drug type segment is expected to hold a major market share during the forecast period in the market.
The major factor hampering growth of the market include no precise diagnostic criteria.
Major players operating in the market include Santen, Novartis Pharmaceuticals, Senju Pharmaceutical, Allakos, iCo Therapeutics, and Akari Therapeutics.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.